Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine/Atropine for Reversal of Neuromuscular Blockade in RARC
NCT03144453Phase 4Unknown
- Sponsor
- IRCCS Regina Elena National Cancer Institute
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by IRCCS Regina Elena National Cancer Institute. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03144453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144453.